Your JM Support Community
Cure JM helps patients and their families navigate life with juvenile myositis.
Cure JM is the global leader in juvenile myositis (JM) research. We are paving the way to better treatments for JM while improving the lives of families affected by the disease.
Juvenile myositis involves a run-away immune response where the body’s immune system attacks its own cells and tissues. With proper treatment and care, children can go on to live their best lives.
Was your child recently diagnosed with juvenile myositis?
We are honored to share our new short film, “Our Mission, Our Impact,” highlighting the key aspects of our mission, working together to make life-changing impacts for the patients and families we serve. Please join us in celebrating the impacts of this progress by making a gift and sharing this video.
It often takes a bit of time for children with juvenile myositis (JM) to get a proper diagnosis. This is due to the fact that
Fundraising doesn’t have to be a daunting task…We’d like to invite our families to join us in putting the “Fun” in fundraising.
Practical tips on how to navigate your child’s school system. Presented by Michelle Best (special education and mental health advocate) and Sue Carpenter (special education
Discover the many ways you can support and connect with Cure JM.
We invite you to get involved with Cure JM. We hope you’ll join us in helping make our mission a success.
Join Our Giving Tuesday Holiday Challenge
Be a Hope Hero!
Join us anytime between now and Giving Tuesday, November 28, to help give JM kids a brighter future.
Together, we’re funding better treatments, care, and support for juvenile myositis.
Finding a Cure and Better Treatments for Juvenile Myositis
Cure JM is accelerating juvenile myositis research at an unprecedented pace. We are pursuing promising new treatments, funding clinical trials, and improving care for patients.
The Chan Zuckerberg Initiative has awarded Cure JM and a consortium of Cure JM-funded researchers a coveted $2 million rare disease research grant to identify new biomarkers in JM and improve precise, personalized care through the identification of cell-to-cell interactions that drive inflammation in juvenile myositis.
You may have heard about the FDA’s ruling, which approved vamorolone as an alternative steroid for use in Duchenne muscular dystrophy.
Vamorolone is a new steroid alternative with fewer side effects than prednisone. The drug aims to preserve the beneficial anti-inflammatory and muscle-strengthening characteristics of corticosteroids, while decreasing some of the unwelcome side effects, including bone fragility, delayed growth, and behavior changes.
ProDerm Study Reports a Milestone in Managing Adult Myositis
Recently, the Progress in Dermatomyositis ProDERM study published in the New England Journal of Medicine reported a milestone in managing adult myositis. With the trial’s favorable results, adult myositis patients have new hope with the approval of Octagam® 10%.
A clinical trial treating patients with juvenile myositis with the drug abatacept resulted in lower disease activity and clinically significant responses in most patients.
“Cure JM has provided us so much support and connected us to so many families that were experiencing or had experienced the exact same thing. That sense of community helped us get through the ups and downs.”
Join Cure JM
Membership is free and we’ll connect you with a network of support, encouragement, and resources.